Biotech / Pharma View all members Browse by Membership Category
3D PARS is a virtual launch pad that provide product driven consultation support to a variety of industries including biotech/pharma. 3D PARS work with core facilities for fast track product development and prototyping efforts.
The goal at Ascribe BioScience is to commercialize small molecules isolated from plant parasitic nematodes as plant biostimulants to control a range of economically important crop diseases. The science behind our product is published in a Nature paper available here: www.nature.com/articles/ncomms8795.
CNYBAC incubates and accelerates university-industry partnerships that discover, design, develop, and deploy innovative products for the bioscience marketplace.
ConSynance is a clinical-stage drug development company. We are committed to developing novel therapeutic solutions for unmet medical needs. Our pipeline includes innovative treatments for nonalcoholic steatohepatitis (NASH), the orphan disease Prader-Willi syndrome (PWS), and irritable bowel syndrome (IBS).
Cormac Life Sciences, LLC (CLS) is a Veterans Affairs and New York State certified Service-Disabled Veteran-Owned Small Business (SDVOSB) delivering life sciences research and support services. CLS provides expertise across a range of biopreparedness disciplines to include biosurveillance, basic and translational sciences, clinical research, and essential support services such as quality assurance, regulatory affairs services and grants management. CLS is led by physician-scientists, technology executives and health care business development experts with established connections across government, industry and academia. CLS’ mission is to support global health security and biopreparedness objectives. CLS is committed to providing innovative, agile, and client-centered solutions with a focus on New York State and U.S. Government clients.
Dynamic Boundaries is a biotechnology company developing a safe and cost-effective injectable treatment for osteoarthritis that provides lasting protection against further joint damage.
Efferent Labs is a preclinical-stage company focused on implantable biosensors. Its CytoComm™ Living Biosensor System uses living cells; a powerful tool to study life processes, to assess cellular function and biological signaling in vivo. The system transmits patient-specific data to the cloud, where it accessible in real-time by clinicians and researchers.
EndoGlow designs and distributes a line of medical devices that integrates Tissue Reveal Technology™ into surgical and medical procedures. Tissue Reveal Technology™ allows the medical team to visualize critical anatomy, appraise relative tissue depth and evaluate subsurface pathology. EndoGlow’s medical devices fluoresce under near infrared imaging which provides enhanced visualization and medical efficiency when it is most needed.
Ichor Therapeutics, Inc. is a biotechnology company and pre-clinical contract research organization headquartered in LaFayette, NY. The company operates two research programs which broadly focus on cancer and eye disease. Ichor also performs contract research for corporations, non-profit organizations, government agencies, and high net worth individuals.
Integrated Tissue Dynamics, LLC (INTiDYN) provides the biopharmaceutical industy novel and proprietary solutions for complex endpoint evaluations in clinical and research tissues. Particularly focused on skin, INTiDYN research aims to produce novel solutions to numerous debilitating human conditions, including chronic pain, diabetes, immuno- and dermato-pathologies, and trauma.
Since Ionica Sciences was founded by Dr. Omar Green and Dr. Joel Tabb in 2013, we have been developing a platform disease diagnostic that has the flexibility to detect vector borne, sexually transmitted, and neurological diseases, among others. Combining well established spectroscopic methods, with new materials tailored for use this setting, and statistical methods, this approach has the potential to change how many diseases are diagnosed.
Their initial target is Lyme disease, the fastest growing vector borne disease in the United States, according to the CDC. The improved test, IonLyme, will provide clinicians critical information not available to them currently, allow Ionica to demonstrate the principle of the platform, and rapidly expand the diseases that can be identified using this cutting edge technology.
Caring for the world, one person at time, inspires and unites the people of Johnson & Johnson. They embrace innovation - bringing ideas, products and services to life to advance the health and well-being of people around the world. They believe in collaboration, and that has led to breakthrough after breakthrough, from medical miracles that have changed lives, to the simple consumer products that make every day a little better. Johnson & Johnson has over 125,000 employess in 60 countries and they are united in a common mission: to help people everywhere live longer, healthier, happier lives.
Kinentia Biosciences was founded in 2007 to utilize its platform chemoinformatics technology called Deep Data Mining (DDM™) to aid our clients in the discovery and development of novel pharmaceutical agents. DDM recognizes key risk factors involved in the drug discovery process and has built in process checks to mitigate this risk. Their team of consultants has extensive experience in the areas of global CRO and CMO management and materials procurement. By combining these capabilities with their platform technology Kinentia can greatly facilitate and mitigate the risk associated with pharmaceutical development.
The Neural Stem Cell Institute (NSCI) is dedicated to developing regenerative stem cell therapies for various diseases of the central nervous system (CNS): the brain, spinal cord and retina, regardless of the cause of injury. Led by MacArthur “Genius” Award winner Dr. Sally Temple who helped discover and define nervous system stem cells, NSCI is the first independent, non-profit stem cell research institute in the USA.
NextCorps is a group of entrepreneurs, advisors, venture capitalists and staff committed to creating the next generation of world-changing Rochester technology companies. Headquartered in iconic Sibley Square, NextCorps provides a space designed for collaboration and “creative collisions” along with the meeting, lab and fabrication resources that your startup will need to thrive.
Based on a recent survey, hospital executives said finding cost savings to meet their current-year objectives is their top challenge.
The supply chain—more specifically, inventory and order management processes—is one place to find those savings. A study from the International Journal of Supply Chain Management shows that inventory and order management costs account for 61 percent of total supply chain costs (or $61 million per year for a typical large healthcare provider).
At ORLink, they know all hospitals want to control their surgical inventory spend. But the monster under the bed is the surgical preference card. So they set out to build a tools set to help control time, tools and materials.
The concept started when their founder, Dr Wayne Colin moved his preference cards from one hospital to another. During the resulting time and hassle he realized that the problem was the preference card itself. And he set out to do something about it.
Diagnostic technology platform - primary markets served: business to business tier one players
Pharmaceutical manufacturing/quality monitoring
Pharmaceutical, skin diseases
Quadrant Biosciences works with top academic institutions, medical researchers and engineers to translate breakthrough findings into thoughtfully developed and scientifically sound assessment applications.
Their evolutionary advancements in brain health assessment, autism and Parkinson’s detection, will have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions going forward. Supported through private and state funding, one of these key technologies, ClearEdge, is currently available in the market and the others are slated for a 2018 release.
At Regeneron employees work every day to bring innovative thinking to the challenge of discovering and developing new medicines. Regeneron’s pursuit has one singular intent: to improve therapeutic outcomes for patients.
Repair Biotechnologies is a biotechnology company with the mission to develop and bring to the clinic therapies that significantly improve human healthspan through targeting the causes of age-related diseases and aging itself.
Sanabit is a breakthrough technology that uses magnetic fields to boost productivity of the cell, resulting in healthier tissue. They make non-invasive, non-chemical products that help wounds heal faster by stimulating the body's natural mechanisms. SANABIT is focused on translating this early breakthrough research into a beta product that will be attractive for a large range of medical applications. Reducing the time a patients spends in the hospital has significant implications for hospital efficiency, patient satisfaction, and cost.
StemCultures is led by a team of dedicated cell biologists, industry technologists and entrepreneurs who are committed to working together to advance life science research. They create, manufacture and distribute reliable reagents that improve the experience of scientists with diverse interests and fields. Their proprietary controlled-release reagents provide a stable micro-environment for improved cell growth.
StemCultures is in partnership with the Neural Stem Cell Institute which possesses decades of research experience, including the lab of Dr. Sally Temple, co-founder of StemCultures, a pioneer credited with discovering stem like cells in the brain in 1989.
The UAlbany Office for Innovation Development and Commercialization helps members of the UAlbany community – faculty, staff and students – increase their impact on society by assisting in:
- Identifying innovations emerging from their research, teaching and service activities that could have broader societal impact;
- Assessing the costs and benefits associated with development and commercialization of the innovation;
- For innovations whose projected benefits exceed projected costs:
- Protecting the intellectual property as appropriate by patent, trademark, and/or copyright;
- Evaluating potential pathways and developing strategies for development and commercialization;
- Finding partners who can participate in further research, development and commercialization;
- Negotiating agreements that provide value to both partners while protecting the rights of U Albany participants and preserving intellectual property assets;
- Helping interested faculty, staff and students in their entrepreneurial pursuits.
Since 2005, Ultradian Diagnostics has been driven by an unmet need for high-quality, pain-free, wearable diagnostic devices capable of lowering costs and improving health care through superior accuracy and performance. Their management team is driven by a vision to provide users and clinicians with diagnostic tools to successfully monitor and manage chronic illnesses in a cost effective manner. Their focus is on developing a flexible device that minimizes sensor drift and signal noise.
An industry leader and innovator in infectious disease diagnostic development, ZeptoMetrix™ Corporation (ZMC) is a fully integrated biotechnology company with products and services that support all phases of Research & Development, Analytical and Diagnostic Studies, Assay Validation & Verification, Quality Control, Comparative Assay Performance Analysis, Service Testing, Manufacturing, BioStorage, Regulatory Submissions and Test Kit Commercialization.
Zetagen Therapeutics Inc., is an early stage regenerative medicine company that is creating bone regeneration solutions for a number of high volume clinical applications for use by orthopedic surgeons. Based on technology developed at SUNY-Upstate Medical University, Zetagen's product addresses the large unmet need for devices that promote safe and robust bone growth in the $4B bone regeneration market. The Zetagen bone regeneration device grows bone by activating a novel molecular pathway in mesenchymal stem cells. The serendipitous discovery of this pathway has led to the commercialization by Zetagen of the first-ever, small molecule-based osteo-inductive technology. As opposed to other products on the market that contain biologic growth
factors, which have declined in use precipitously due to high cancer risk and other side effects, Zetagen's solution is more effective at growing bone, has a unique safety profile, and is significantly less costly to manufacture.
Optimizing enzyme immobilization to create unique, sustainable and responsible processes for high performance biocatalysis.